BeiGene (BGNE)
(Delayed Data from NSDQ)
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Zacks News
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
by Zacks Equity Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
Novartis (NVS) Collaborates With BeiGene for Oncology Drug
by Zacks Equity Research
Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.
Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review
by Zacks Equity Research
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
by Zacks Equity Research
The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
by Zacks Equity Research
The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion
by Zacks Equity Research
The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers
by Zacks Equity Research
Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.
Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes
by Zacks Equity Research
Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.
Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook
by Zacks Equity Research
Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
by Zacks Equity Research
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene
by Zacks Equity Research
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy
by Zacks Equity Research
BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
BeiGene's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in BeiGene.
Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma
by Zacks Equity Research
Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.
What Makes BeiGene, Ltd. (BGNE) a New Buy Stock
by Zacks Equity Research
BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Amgen (AMGN) Invests Further in China-Based Oncology Partner
by Zacks Equity Research
Amgen (AMGN) announces additional investment of approximately $421 million in BeiGene. The companies have a collaboration for oncology products signed in 2019.
Leap Therapeutics Surges on License Agreement With BieGene
by Zacks Equity Research
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China
by Zacks Equity Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.